Related Experiment Video

Updated: Jan 10, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K

OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR

Xiaofen Ma1,2, Xiaoyu Hua2,3,4, Xiao Peng2,3,4

  • 1Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, School of Pharmacy, Xinjiang Medical University, Ürümqi 830000, China.

Toxins
|November 26, 2025
PubMed

Insights

Opicalcin1 (OpiCa1) reduces cardiac cell viability and promotes apoptosis by inhibiting the PI3K/Akt pathway. Despite this, high doses show minimal systemic toxicity, supporting calcin-based cardiac disease therapies.

Area of Science:

  • Cardiovascular Biology
  • Molecular Pharmacology
  • Cellular Toxicology

Background:

  • Calcins are novel peptide ligands for ryanodine receptors (RyRs) with therapeutic potential for cardiac diseases.
  • The non-RyR-mediated biological effects and mechanisms of calcins are largely unknown.

Purpose of the Study:

  • To investigate the effects of Opicalcin1 (OpiCa1), a potent calcin, on cardiomyocyte viability and explore its underlying mechanisms.
  • To assess the in vivo systemic toxicity of OpiCa1.

Main Methods:

  • Utilized H9c2 cardiomyocytes for in vitro studies.
  • Employed transcriptomics and Western blot analyses to identify molecular pathways.
  • Conducted acute and chronic in vivo studies in animal models.

Main Results:

  • OpiCa1 reduced cytosolic Ca2+ but decreased H9c2 cell viability and induced apoptosis.
  • Suppression of the PI3K/Akt pathway was identified as the mechanism for OpiCa1's cellular effects.
  • High-dose OpiCa1 (≥50 mg/kg i.v.) showed minimal impact on body weight, histopathology, and organ indices, with subtle serum indicator alterations.

Conclusions:

  • OpiCa1 modulates cardiomyocyte viability via PI3K/Akt inhibition.
  • OpiCa1 exhibits minimal systemic toxicity in vivo.
  • Findings provide insights into non-RyR actions of calcins and toxicological data for calcin-based cardiac therapies.
Keywords:
Ca2+OpiCa1PI3K/Akt signalingapoptosisryanodine receptortranscriptomics

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.1K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
378